Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $12.87 million. The enterprise value is $9.69 million.
Important Dates
The next estimated earnings date is Friday, May 8, 2026, after market close.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 4.23 million shares outstanding. The number of shares has increased by 26.33% in one year.
| Current Share Class | 4.23M |
| Shares Outstanding | 4.23M |
| Shares Change (YoY) | +26.33% |
| Shares Change (QoQ) | +18.17% |
| Owned by Insiders (%) | 17.41% |
| Owned by Institutions (%) | 18.57% |
| Float | 3.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.24 |
| Forward PS | n/a |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.15
| Current Ratio | 5.15 |
| Quick Ratio | 4.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -39.34% and return on invested capital (ROIC) is -34.66%.
| Return on Equity (ROE) | -39.34% |
| Return on Assets (ROA) | -31.78% |
| Return on Invested Capital (ROIC) | -34.66% |
| Return on Capital Employed (ROCE) | -54.74% |
| Weighted Average Cost of Capital (WACC) | 9.15% |
| Revenue Per Employee | $2.07M |
| Profits Per Employee | -$3.53M |
| Employee Count | 1 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.33% in the last 52 weeks. The beta is 0.89, so CYCN's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | +13.33% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 2.08 |
| Relative Strength Index (RSI) | 54.29 |
| Average Volume (20 Days) | 13,828,591 |
Short Selling Information
The latest short interest is 113,448, so 2.68% of the outstanding shares have been sold short.
| Short Interest | 113,448 |
| Short Previous Month | 84,548 |
| Short % of Shares Out | 2.68% |
| Short % of Float | 3.25% |
| Short Ratio (days to cover) | 2.95 |
Income Statement
In the last 12 months, CYCN had revenue of $2.07 million and -$3.53 million in losses. Loss per share was -$1.11.
| Revenue | 2.07M |
| Gross Profit | 1.12M |
| Operating Income | -4.97M |
| Pretax Income | -3.53M |
| Net Income | -3.53M |
| EBITDA | n/a |
| EBIT | -4.97M |
| Loss Per Share | -$1.11 |
Full Income StatementBalance Sheet
The company has $3.24 million in cash and n/a in debt, with a net cash position of $3.24 million or $0.77 per share.
| Cash & Cash Equivalents | 3.24M |
| Total Debt | n/a |
| Net Cash | 3.24M |
| Net Cash Per Share | $0.77 |
| Equity (Book Value) | 9.09M |
| Book Value Per Share | 2.38 |
| Working Capital | 3.74M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.31M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -3.31M |
| FCF Per Share | -$0.78 |
Full Cash Flow StatementMargins
Gross margin is 53.76%, with operating and profit margins of -239.78% and -170.11%.
| Gross Margin | 53.76% |
| Operating Margin | -239.78% |
| Pretax Margin | -170.11% |
| Profit Margin | -170.11% |
| EBITDA Margin | n/a |
| EBIT Margin | -239.78% |
| FCF Margin | n/a |
Dividends & Yields
CYCN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.33% |
| Shareholder Yield | -26.33% |
| Earnings Yield | -27.28% |
| FCF Yield | -25.63% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 16, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 16, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
CYCN has an Altman Z-Score of -33.75 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -33.75 |
| Piotroski F-Score | 2 |
